Compare
NRC Health vs MaxCyte, Inc. vs OmniAb, Inc. vs Medpace Holdings, Inc.
| Latest fiscal year | NRC Health NRC | MaxCyte, Inc. MXCT | OmniAb, Inc. OABI | Medpace Holdings, Inc. MEDP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $137.39M | $33.03M | $18.67M | $2.53B |
| Revenue growth (YoY) | -4.0% | -14.5% | -29.3% | +20.0% |
| Gross margin | n/a | 81.2% | n/a | n/a |
| Operating margin | 16.4% | -157.1% | -369.5% | 21.1% |
| Net margin | 8.4% | -135.1% | -347.0% | 17.8% |
| Net income | $11.60M | -$44.63M | -$64.78M | $451.12M |
| EPS (Diluted) | $50.00 | -$0.42 | -$0.57 | $15.28 |
| Operating cash flow | $26.45M | -$34.41M | -$36.45M | $713.22M |
| Free cash flow | $15.74M | -$36.18M | -$37.02M | $681.87M |
| Cash & equivalents | $4.14M | $20.07M | $25.52M | $497.05M |
| Total assets | $134.88M | $202.51M | $300.91M | $1.98B |
| Total liabilities | $120.89M | $31.02M | $33.89M | $1.52B |
| Shareholders' equity | $13.99M | $171.49M | $267.03M | $459.07M |
| Return on year-end equity | 82.9% | -26.0% | -24.3% | 98.3% |
| Shares outstanding | 22.64M | 106.79M | 144.31M | 28.37M |
Revenue, most recent five fiscal years
| Fiscal year | NRC Health | MaxCyte, Inc. | OmniAb, Inc. | Medpace Holdings, Inc. |
|---|---|---|---|---|
| Latest | $137.39M Ended 2025-12-31 | $33.03M Ended 2025-12-31 | $18.67M Ended 2025-12-31 | $2.53B Ended 2025-12-31 |
| 1 year earlier | $143.06M Ended 2024-12-31 | $38.63M Ended 2024-12-31 | $26.39M Ended 2024-12-31 | $2.11B Ended 2024-12-31 |
| 2 years earlier | $148.58M Ended 2023-12-31 | $41.29M Ended 2023-12-31 | $34.16M Ended 2023-12-31 | $1.89B Ended 2023-12-31 |
| 3 years earlier | $151.57M Ended 2022-12-31 | $44.26M Ended 2022-12-31 | $59.08M Ended 2022-12-31 | $1.46B Ended 2022-12-31 |
| 4 years earlier | $147.95M Ended 2021-12-31 | $33.89M Ended 2021-12-31 | $34.75M Ended 2021-12-31 | $1.14B Ended 2021-12-31 |